Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney  by Narkar, Vihang et al.
Kidney International, Vol. 66 (2004), pp. 633–640
Dopamine D2-like receptor agonist bromocriptine protects
against ischemia/reperfusion injury in rat kidney
VIHANG NARKAR,1,2 OKSANA KUNDUZOVA,2 TAHIR HUSSAIN, CLAUDIE CAMBON,
ANGELO PARINI, and MUSTAFA LOKHANDWALA
Heart and Kidney Institute College of Pharmacy, University of Houston, Houston, Texas; and INSERM U 388,
Pharm. Moleculaire et Physiopathologie Renale Institut Louis Bugnard, Toulouse, France
Dopamine D2-like receptor agonist bromocriptine protects
against ischemia/reperfusion injury in rat kidney.
Background. Dopamine, via activation of D1-like and D2-
like receptors, plays an important role in the regulation
of renal sodium excretion. Recently, we demonstrated that
dopamine D2-like receptor agonist (bromocriptine) stimu-
lates p44/42 mitogen-activated protein kinases (MAPKs) and
Na+,K+ATPase (NKA) activity in proximal tubular epithe-
lial cells. Since both these parameters are compromised in is-
chemia/reperfusion (I/R) injury to the kidney, we investigated
whether bromocriptine protects against the injury.
Methods. In this study we used unilateral rat model of renal
I/R injury. The Sprague-Dawley rats were divided into vehi-
cle and bromocriptine groups. The vehicle and bromocriptine
group was treated with vehicle and bromocriptine (500 lg/kg
intravenously), respectively, 15 minutes before the induction of
unilateral ischemia followed by 24- or 48-hour reperfusion. At
the end of 24 or 48 hours the animals were sacrificed to collect
control and ischemic kidney cortices, in which necrosis, apop-
tosis, NKA activity, NKA a1 subunit expression, and p44/42
MAPK phosphorylation were measured.
Results. We found extensive necrosis, apoptosis, and de-
creased NKA activity (with no change in a1 subunit) in the is-
chemic kidney cortex compared to the nonischemic cortex from
the vehicle-treated rats as early as 24 hours post-reperfusion. In
contrast, I/R injury–induced necrotic, apoptotic, and decrease in
NKA activity were absent in the outer cortex of bromocriptine-
treated rats after 24 or 48 hours. Interestingly, we detected
significantly higher phosphorylation of p44/42 MAPKs in con-
trol and ischemic kidneys of bromocriptine-treated rats com-
pared to those of vehicle-treated rats.
1Dr. Narkar’s present address is Integrative Biology and Pharmacology,
University of Texas Medical School-Houston, 6431 Fannin St., Houston,
TX 77030.
2These authors contributed equally to this work.
Key words: bromocriptine, p44/42 MAPK, ischemia/reperfusion injury,
kidney.
Received for publication September 11, 2003
and in revised form January 2, 2004, and February 16, 2004
Accepted for publication March 1, 2003
C© 2004 by the International Society of Nephrology
Conclusion. Therefore, bromocriptine, a D2-like receptor ag-
onist, may protect against I/R injury to proximal tubules of the
kidney, via p44/42 MAPK activation.
Ischemia/reperfusion (I/R) injury in kidney is one of
the common causes of acute renal failure. Renal I/R in-
jury is usually associated with decreases in renal blood
flow (RBF) and glomerular filtration rate (GFR), an in-
crease in fractional excretion of sodium, and increased
serum creatinine and blood urea nitrogen (BUN) levels
[1–5]. These functional defects in the ischemic kidney are
in part caused by necrosis and apoptosis of the tubular ep-
ithelial cells during I/R injury [6–8]. It has been suggested
that proximal tubules and medullary thick ascending limb
sustain maximum damage during I/R injury, with proxi-
mal tubules being most susceptible of the two [9–11].
Multiple cellular factors are involved in the post-I/R
injury events, which lead to acute renal failure [12–14].
Recently, several groups have begun to explore the role
of mitogen-activated protein kinases (MAPKs) in I/R in-
jury [4, 5, 10, 15–17]. MAPKs are a class of protein ki-
nases, which play an important role in the determination
of cell survival. While p44/42 MAPKs attenuate apopto-
sis, p38 and JNK promote apoptosis [18]. The differential
regulation of these three MAPKs is reported in I/R injury
to cardiac myocytes [16]. Further, Di Mari et al demon-
strated that differential regulation of p44/42, p38 and JNK
MAPKs determines the fate of the tubular epithelial cells
in renal I/R injury [10]. More specifically, selective acti-
vation of JNK, but not of p44/42 MAPK, leads to ex-
tensive apoptosis observed in the proximal tubules after
I/R injury [10, 17]. Therefore, drugs that activate p44/42
MAPKs and/or inactivate JNK may protect the kidney,
especially the proximal tubules, against I/R injury.
Dopamine plays an important role in the regulation
of renal function [19, 20]. Moreover, the in vivo and in
vitro pharmacologic effects of dopamine receptor ago-
nists in the kidney have been extensively studied [19, 20].
We recently showed that bromocriptine (D2-like receptor
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agonist) stimulates p44/42 MAPKs in the proximal
tubules of the kidney [21, 22], which is a potential target
to counter I/R injury. Since proximal tubules are maxi-
mally affected in the course of renal I/R injury [9–11], we
hypothesized that bromocriptine may protect against I/R
injury to the proximal tubules of the kidney.
The proposed hypothesis was tested using unilateral rat
model of renal I/R injury. In this model, one kidney serves
as a sham control and the other kidney is subjected to
45 minutes of ischemia followed by reperfusion. Using the
unilateral rat model, we previously showed that the kid-
ney subjected to I/R injury undergoes extensive necrosis
and apoptosis compared to sham operated kidney within
24 hours after reperfusion [17, 23]. Therefore, in studying
the reno-protective effects of bromocriptine, we evalu-
ated necrosis and apoptosis in rat kidney as biomarkers
of I/R injury. Moreover, in terms of sodium handling, I/R
injury induces the loss of major sodium transporters in
the kidney and leads to an increase in fractional sodium
excretion [2]. Interestingly, bromocriptine increases the
activity of at least one such transporter Na+, K+,
ATPase (NKA) via p44/42 MAPK pathway in renal prox-
imal tubules [22]. On the basis of this observation, we ad-
ditionally measured the effect of bromocriptine on NKA
activity and protein expression in I/R injury.
The experiments were performed in Sprague-Dawley
rats treated with vehicle or bromocriptine before in-
duction of I/R injury. In both groups, the above three
parameters were measured in the outer renal cortical re-
gions (rich in proximal tubules) of sham control and I/R
injury kidney. Furthermore, p44/42 phosphorylation (ac-
tivation) was also measured in both groups to examine
whether its induction coincided with the protective ef-
fects of bromocriptine in I/R injury.
METHODS
All animal experiments were carried out according to
the principles of Laboratory Animal Care formulated by
the National Society for Medical Research and the Guide
for the Care and Use of Laboratory Animals (National
Institutes of Health publication 86–23, revised 1989, au-
thorization 00577, 1989, Paris, France). Male Sprague-
Dawley rats weighing 140 to 190 g (Harlan ZI Du
Malcourlet, France) were housed individually in standard
laboratory cages with ad libitum access to food and water.
Unilateral renal I/R injury in Sprague-Dawley rats
In this procedure, the rats were anesthetized with
sodium pentobarbital (60 mg/kg intraperitoneally). Next,
the jugular vein was cannulated with a polyethylene
catheter (PE-10) for the administration of the drug. Is-
chemia was induced by clamping the right renal artery
with nontraumatic vascular clip for 45 minutes. During
Group I
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Histology
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Fig. 1. Schematic representation of induction of renal ischemic/
reperfusion (I/R) injury.
the operation, the animals were kept on a surgical ther-
mostatically controlled table at 38 ± 1◦C under anesthe-
sia. After surgery the animals were returned to the cages,
where they had free access to food and water. The rats
were divided into two sets (24-hour and 48-hour sets),
with each set having two groups. In each set, one group
of animals (N = 6) was given bromocriptine (500 lg/kg
intravenously) 15 minutes prior to the renal artery occlu-
sion, whereas a second group (N = 6) received vehicle.
Experimental protocol is explained in Figure 1. The con-
tralateral nonischemic kidney serves as a control to the is-
chemic kidney. The kidneys from 24- or 48-hour set of rats
were removed after 24 hours or 48 hours of reperfusion,
respectively, and divided lengthways into two parts. One
part was suspended in ice-cold modified Krebs-Henseleit
buffer (KHB) solution [22] for biochemical assays and
the second was fixed in Dubose solution for histologic
examination.
Histologic examination
For histologic examination, Dubose-fixed and paraffin-
embedded kidney specimens (5 lm) were stained with
hematoxylin and eosin. Histologic changes were evalu-
ated by measurement of tissue necrosis graded on an A
to F scale in relation to the extent of kidney damage: A,
none; B, up to 10%; C, from 10% to 25%; D, from 25% to
50%; E, from 50% to 75%; and F, more than 75%. Tubu-
lar necrosis was assessed in the renal cortex at 24 hours
and 48 hours after I/R.
TUNEL assay
The sections of kidney embedded in paraffin were de-
paraffinized in toluene and a graded series of ethanol.
DNA fragmentation (apoptosis) was visualized in situ
on fixed tissues by the terminal transferase-mediated
deoxyuridine triphosphate (dUTP) nick-end labeling
(TUNEL) procedure, using the apoptosis detection
kit of Promega (Madison, WI, USA). Briefly, the de-
paraffinized sections were incubated in proteinase K
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(20 lg/mL) solution to permeabilize the tissues, rinsed,
and further fixed in paraformaldehyde (4%). The sections
were incubated with 1 lL of terminal deoxynucleotidyl
transferase (25 U/lL) and fluorescein-12-dUTP in equili-
bration buffer [25 mmol/L Tris-HCl, pH 6.6; 200 mmol/L
potassium cacodylate, pH 6.6, 2.5 mmol/L cobalt chlo-
ride, 0.25 mg/mL bovine serum albumin (BSA), and 0.2
mmol/L dithiothreitol (DTT)] for 1 hour at 37◦C. Further,
the slides were rinsed four times in standard sodium cit-
rate (SSC) and phosphate-buffered saline (PBS) and im-
mersed in 40 mL propidium iodide solution (1 lg/lL) for
15 minutes. The positive control was treated by DNAse I
(1 lg/lL) before being processed with the TUNEL pro-
cedure. The TUNEL-positive cells were counted under
fluorescence microscope and data represented as percent
of cells that stained TUNEL positive.
Preparation of cortical homogenate
The kidneys isolated from the above groups were im-
mediately transferred to 5 mL ice-cold KHB solution
containing protease inhibitor cocktail. Outer cortex was
separated from each kidney, to obtain the portion rich
in proximal tubules. The isolated cortical slices were ho-
mogenized using Wheaton’s homogenizer at setting 7
for 20 strokes, and the protein concentration of the ho-
mogenate measured. The NKA activity, NKA a1-subunit
expression, and p44/42 MAPKs phosphorylation were
measured in the cortical homogenate.
NKA activity in cortical homogenate
The NKA activity was measured in cortical ho-
mogenate (1 mg/mL) as previously described [28]. The
reaction mixture was carried out in 1.025 mL of as-
say buffer [37.5 mmol/L immidazole buffer, 70 mmol/L
NaCl, 5 mmol/L KCl, 1 mmol/L Na ethylenediaminete-
traacetic acid (EDTA), 5 mmol/L MgCl2, 6 mmol/L
NaN3, 75 mmol/L Tris-HCl] using 0.1 mL (0.1 mg pro-
tein) of cortical homogenate. The reaction was initi-
ated by adding 4 mmol/L adenosine triphosphate (ATP).
Ouabain-insensitive ATPase activity was determined in
parallel using an assay buffer containing 150 mmol/L
Tris-HCl, 1 mmol/L ouabain instead of NaCl and KCl.
The reaction was carried out at 37◦C for 15 minutes
and terminated by adding 0.05 mL of ice-cold 50%
trichloroacetic acid (TCA). The NKA activity was mea-
sured as the function of liberated inorganic phosphate
(Pi) in triplicates. The NKA activity was calculated as
the difference between the total and ouabain-insensitive
ATPase activity and was represented as Pi lmol/mg
protein/min.
NKA a1 subunits and p44/42 MAPKs in cortical
homogenate by Western blotting
Loading samples were prepared for western blotting
containing sodium dodecyl sulfate (SDS)-Laemmli (4×)
Table 1. Histologic changes
Vehicle + I/R Bromocriptine + I/R
Grading Tubular
scale necrosis % 24 hours 48 hours 24 hours 48 hours
A 0 – – 4 3
B 0–10 – – 1 2
C 10–25 1 – – –
D 25–50 1 1 – –
E 50–75 2 2 – –
F >75 1 2 – –
I/R is ischemic/reperfusion injury. Histologic changes were evaluated by
measuring of tissue necrosis graded on a 0 to 5 scale in relation to the extent
of kidney damage: A, none; B, up to 10%; C, from 10% to 25%; D, from
25% to 50%; E, from 50% to 75%; and F, more than 75%. The grading was
performed in cortical regions of ischemic kidneys from vehicle-treated and
bromocriptine-treated rats.
(0.05 mL), bromophenol blue (0.02 mL), corticular ho-
mogenate (0.1 mL), and water (0.03 mL). Further, the
loading samples were resolved by SDS-polyacrylamide
gel electrophoresis (PAGE) and transferred to polyvinyli-
dene fluoride (PVDF) membrane. The NKA a1 sub-
units, phospho-p44/42 MAPKs, and total MAPKs on
the PVDF membrane were detected using mono-
clonal NKA a1-subunit antibody (Research Diagnos-
tics, Flanders, NJ, USA), anti-phospho-p44/42 MAPKs
antibody (Promega), and anti-p42 MAPKs antibody
(Santa Cruz Biotechonology, Santa Cruz, CA, USA),
respectively. Where indicated, the Western blots were
subjected to densitometric analysis using Scion Image
software. The MAPKs data are represented as the den-
sitometric ratio of phospho- to total-p42 MAPKs.
Data analysis
Where applicable, data are presented as mean ± SEM
of number (N) of experiments. Statistical analysis was
done using unpaired Student t test or one-way analysis
of variance (ANOVA) as explained in the figure legends.
The difference was considered statistically significant at
P < 0.05.
RESULTS
Necrosis in the cortical slices of
vehicle- and bromocriptine-treated rats
The histologic alterations induced by unilateral renal
ischemia were evaluated at 24 hours and 48 hours of
reperfusion. Extensive necrosis was observed in outer
cortex of ischemic compared to contralateral kidneys of
vehicle-treated rats after 24 hours of reperfusion (Fig. 2A
and B, Table 1) and 48 hours of reperfusion (Table 1).
On the other hand, the histology of ischemic cortex from
bromocriptine (500 lg/kg intravenously)-treated rats was
similar to contralateral kidneys after 24 hours (Fig. 2C
and D, Table 1) and 48 hours (Table 1) of reperfusion.
Bromocriptine did not produce any detectable histologic
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Fig. 2. Histology in cortical region of kidney
slices of unilateral I/R rat model. Representa-
tive light micrographs (magnification, 40×) of
hematoxylin and eosin stained sections show-
ing morphologic features of cortical region 24
hours post I/R injury. In vehicle-treated rats,
the ischemic cortical slices (B) showed ex-
tensive necrosis (indicated by arrows) com-
pared to the contralateral kidney (A). The
histomorphology of bromocriptine-treated is-
chemic kidneys (D) was normal and indistin-
guishable from contralateral control kidneys
(C). Similar results were obtained from 5 an-
imals.
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Fig. 3. Apoptosis in cortical region of kid-
ney slices of unilateral ischemic/reperfusion
(I/R) injury rat model. Apoptosis was deter-
mined in 24 hours post-I/R cortical kidney
slices. Compared to the contralateral cortical
slices (A), in vehicle-treated rats, the ischemic
cortical slices (B) showed extensive TUNEL-
positive staining. (C) The contralateral cor-
tical slices of bromocriptine-treated rats are
represented. In bromocriptine-treated rats
low TUNEL-positive staining was detected in
the ischemic cortical slices (D). (E) Data rep-
resented as % TUNEL-positive cells (N = 3).
∗ and # represent statistically significant dif-
ference between groups compared (P < 0.05)
[one-way analysis of variance (ANOVA); post
hoc, Tukey’s multiple comparision test].
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Fig. 4. Detection of NKA activity and a1 subunits in renal cortical
homogenates of unilateral ischemic/reperfusion (I/R) rat model. NKA
activity and a1 subunit levels were determined in cortical homogenates
obtained from the vehicle-treated and bromocriptine-treated rats 24
hours post-I/R. (A) In vehicle-treated rats, the NKA activity in is-
chemic cortical homogenate (IR) was significantly lower than in the
contralateral cortical homogenate (Co). (B) In bromocriptine-treated
rats, NKA activity was similar between contralateral and ischemic cor-
tical homogenates. Data are represented as inorganic phosphate (Pi)
released in lmol/mg/min. ∗Represents significant difference between
Co and IR in vehicle-treated rats (P < 0.05) (unpaired Student t test).
(C) Representative Western blot of NKA a1 subunit expression in cor-
tical homogenates of vehicle-treated and bromocriptine-treated rats 24
hours post I/R. Similar results were obtained in N = 4 animals.
abnormalities in the contralateral kidney. This result in-
dicates that bromocriptine prevented cortical necrosis in
renal I/R injury after 24 and 48 hours post-reperfusion.
Apoptosis in the cortical slices of
vehicle- and bromocriptine-treated rats
Apoptosis was detected by TUNEL assay performed in
the cortical slices from the contralateral and ischemic kid-
neys. Extensive TUNEL-positive staining was observed
in the outer cortex of ischemic compared to contralateral
kidney of vehicle-treated rats (Fig. 3A and B). In con-
trast, low level of TUNEL-positive staining was detected
in contralateral and ischemic kidneys of bromocriptine-
treated rats (Fig. 3C and D). The percent of cells that
were TUNEL-positive in each group is represented in
Figure 3E. This result indicates that bromocriptine pre-
vented cortical apoptosis in renal I/R injury.
NKA activity in the cortical homogenates of
vehicle- and bromocriptine-treated rats
NKA activity was measured as described in the cortical
homogenates of the kidney. It was found that the NKA
activity in the cortical homogenate from the ischemic
kidney was decreased as compared to the contralateral
kidney in vehicle-treated rats (Fig. 4A). NKA activity
in the bromocriptine-treated rats was same in both the
contralateral and the ischemic kidney. Moreover, this ac-
tivity was similar to that of the contralateral kidney of
vehicle-treated rats (Fig. 4B). This result indicates that
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Fig. 5. Determination of p44/42 mitogen-activated protein kinases
(MAPKs) phosphorylation in renal cortical homogenates of unilateral
ischemic/reperfusion (I/R) rat model. (A) In vehicle-treated rats, low
phosphorylation was detected in contralateral (1) and ischemic (2) corti-
cal homogenate. On the other hand, bromocriptine-treated rats showed
extensive phosphorylation in contralateral (3) and ischemic (4) cortical
homogenate (upper panel). The total-p42 MAPKs was similar in all the
groups compared (1, 2, 3, and 4) (lower panel). The above are represen-
tative blots. Similar results were obtained from N = 4 sets of animals.
(B) Data represented as average (mean ± SEM) ratio of phospho-p42
to total p42 MAPKs from N = 4 animals. (P < 0.05) [one-way analysis
of variance (ANOVA); post hoc, Newman-Keuls multiple comparison
test).
bromocriptine prevents the loss of NKA activity in the
cortex of the ischemic kidney.
To test the possibility that change in the NKA ac-
tivity is due to modified protein levels, we measured
the expression of catalytic NKA a1 subunit in the
above homogenates. We did not detect any difference
in the expression of NKA a1 subunits in the contralat-
eral or ischemic cortical homogenates from vehicle and
bromocriptine-treated animals (Fig 4C). Therefore, the
changes in NKA activity are independent of the level of
NKA a1 subunits in the cortex.
The p44/42 MAPKs activity in the
vehicle- and bromocriptine-treated rats
The p44/42 MAPKs activity was measured as the func-
tion of p44/42 MAPKs phosphorylation in the cortical ho-
mogenates of the kidney. In the vehicle-treated rats, there
was low detectable phosphorylation of p44/42 MAPKs in
both the control and ischemic cortices (Fig. 5A, upper
panel). The total p42 MAPKs in all the homogenates
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was similar (Fig. 5A, lower panel). In bromocriptine-
treated rats the phosphorylation of p44/42 MAPKs was
similar in both the contralateral and ischemic kidney
(Fig. 5A, upper panel). Moreover, the phosphoryla-
tion of p44/42 MAPKs in the bromocriptine-treated rats
was significantly higher than the phosphorylation in the
vehicle-treated rats. This was not simply due to more
p44/42 MAPKs protein, as the total protein loaded was
same in vehicle-treated and bromocriptine-treated rats
(Fig. 5A, lower panel). Thus, bromocriptine increases
phospho-p44/42 MAPKs in both contralateral and
ischemic cortices of bromocriptine-treated rats as com-
pared to vehicle-treated rats. The above data are repre-
sented as densitometric ratio of phospho-p42 to total-p42
MAPKs (Fig. 5B).
DISCUSSION
This study was designed to explore the potential of syn-
thetic dopamine D2-like receptor agonist, bromocriptine,
to protect against experimental I/R injury to the renal
proximal tubules. We found that I/R injury caused necro-
sis, apoptosis, and loss of NKA activity in the outer cortex
of the kidney, which is rich in proximal tubules. Inter-
estingly, pretreatment of the animals with bromocriptine
prevented necrosis, apoptosis, and loss of NKA activity
associated with I/R injury in proximal tubular regions of
the kidney. This protective effect may be due to the ac-
tivation of p44/42 MAPKs in the bromocriptine-treated
kidney.
I/R injury is known to induce differential activation
of various MAPKs in different segments of the kidney
nephron [10]. Thus, selective activation of JNK leads to
apoptosis of tubular cells, whereas activation of p44/42
MAPKs renders the cells viable [10]. It was suggested
that I/R injury leads to activation of JNK and not p44/42
MAPKs in proximal tubules, making them more sus-
ceptible to apoptosis [10, 17]. In another study, a brief
ischemic preconditioning [4] to kidney or urethral ob-
struction [5] prior to a second ischemia protected the kid-
ney morphologically, as well as functionally against I/R
injury. In these studies it was found that either pretreat-
ment primes the kidney such that, during the second I/R
injury there is decreased p38/JNK activation and/or in-
creased p44/42 MAPKs stimulation. Alternatively, phar-
macologic interventions which protect against renal I/R
injury also increase p44/42 MAPKs in the kidney [10,
17]. Since bromocriptine activates p44/42 MAPKs in re-
nal proximal tubular cells [21, 22], which are known to be
maximally susceptible to I/R injury, it was logical to study
the effects of bromocriptine in this pathophysiologic
situation.
We measured the effect of bromocriptine pretreatment
on I/R injury–induced necrosis, apoptosis, and down-
regulation of NKA activity in the proximal tubules of
the kidney. We found that unilateral I/R injury to kid-
ney caused extensive necrosis by 24 hours in the cortex
(rich in proximal tubules) of ischemic kidney as com-
pared to the control kidney. This observation was in
concert with previous reports [8, 17, 23]. When the ani-
mals were pretreated with bromocriptine, the kidney did
not undergo necrosis, indicating the protective effect of
bromocriptine.
In addition to necrosis, unilateral I/R injury caused
apoptosis in the cortex of the ischemic kidney as com-
pared to the control kidney in the vehicle-treated rats.
Pretreatment of the rats with bromocriptine prevented
I/R injury–induced apoptosis in the kidney. This pro-
tective effect of bromocriptine can be attributed to ac-
tivation of p44/42 MAPKs. As mentioned above, JNK
is predominantly activated in the cortex during I/R in-
jury, which predisposes the proximal tubules to apoptotic
death [10]. By activating p44/42 MAPKs, which are anti-
apoptotic, bromocriptine might cancel out or balance the
effect of JNK.
In concert with some previous reports [24, 25], we
found that the NKA activity in the ischemic cortex was
decreased as compared to the contralateral nonischemic
cortex. However, our results contradict alternative stud-
ies which report no change or actual increase in the NKA
activity in the kidney [26, 27]. This discrepancy may be
associated with the differences in the models of I/R injury
used or due to the use of whole kidney lysate versus cor-
tical lysates for measuring NKA activity. Nevertheless,
pretreatment of the animals with bromocriptine in our
experiments prevented the loss of NKA activity in I/R in-
jury. Unlike the NKA activity, the expression of catalytic
NKA a1 subunit remained constant in all the treatment
groups. The consistent expression of NKA a1 subunit
suggests that bromocriptine restores NKA activity with-
out changing the protein expression. Interestingly, earlier
studies done in our laboratory show that bromocriptine
stimulates NKA activity via p44/42 MAPKs-dependent
recruitment of NKA a1 subunits to the proximal tubular
membrane in the kidney [21, 22, 28, 29]. It is possible that
bromocriptine may prevent the loss of NKA activity in
renal I/R injury by similar mechanism. Moreover, mainte-
nance of NKA activity in the proximal tubular membrane
may partially prevent the increase in fractional excretion
of sodium observed during I/R injury [2].
As previously reported, we found that there was lower
phospho (active)-p44/42 MAPKs in ischemic cortex of
vehicle-treated animals [10]. On the other hand, ro-
bust increase in phospho-p44/42 MAPKs was observed
in both the ischemic and the control non-ischemic kid-
neys of bromocriptine-treated animals. Further, acti-
vation of p44/42 MAPKs in the bromocriptine-treated
animals were concomitant with the protection against
I/R injury (at the level of necrosis, apoptosis, and NKA
activity) in the same animals. In terms of proapoptotic
Narkar et al: Bromocriptine and renal ischemia/reperfusion injury 639
MAPKs, several drugs protect against I/R injury by de-
creasing JNK activity in addition to increasing that of
p44/42 MAPK [10, 17, 30–33]. However, in experiments
done in our lab, bromocriptine did not decrease the el-
evated JNK activity in the ischemic cortex (data not
shown). Therefore, bromocriptine may protect against re-
nal I/R injury by increasing antiapoptotic p44/42 MAPKs
activity, without additionally modifying proapoptotic
JNK activity.
It is noteworthy that certain studies suggest the in-
creased renal phospho-p44/42 MAPKs to be actually
responsible for I/R injury [31, 34]. Moreover, in the
same studies reno-protective agents such as nitric oxide
donors protect against renal I/R injury and simultane-
ously decrease phospho-p44/42 MAPKs in the ischemic
kidneys [31, 34]. At this point it is hard to explain the
discrepancy between these reports and our observations.
However, there are several differences between our ex-
periments and ones performed in these studies at levels
such as the model of I/R injury and time of phospho-
p44/42 MAPK measurement, which can account for
different observations. Moreover, as mentioned above,
we detected increased phospho-p44/42 MAPKs in the
control kidney of bromocriptine-treated animals, which
showed no signs of necrosis or apoptosis. Therefore, it
is more likely that p44/42 MAPKs are protective rather
than causative in renal I/R injury.
The activation of p44/42 MAPKs may not be the sole
mechanism for the protective effects of bromocriptine.
It is interesting to note that the protective effects of
bromocriptine and other dopamine D2-like receptor ag-
onist against cerebral I/R injury have been previously
reported [35, 36, 37]. Multiple mechanisms such as (1)
inhibition of dopamine release [38], (2) activation of su-
peroxide dismutase/free radical scavenging [39, 40, 41,
42, 43], and (3) activation of antiapoptotic factors [35]
are responsible for neuroprotective effects of dopamine
D2-like receptor agonists. It is likely that similar mecha-
nisms, in addition to the one we have described, may also
play a role in the protection of proximal tubules during
I/R injury.
CONCLUSION
Our results show that bromocriptine, a dopamine D2-
like receptor agonist, protects against renal I/R injury.
Further, this protective effect may primarily involve ac-
tivation of p44/42 MAPK. Additional studies are neces-
sary to explore the potential of bromocriptine in treating
post-I/R acute renal failure.
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